Press release
Odense, Denmark – July 23, 2026 – TIDES Europe 2026 is Europe’s biggest event for oligonucleotides, peptides, mRNA, and drug delivery showcasing cutting-edge strategies in discovery, development, and manufacturing to accelerate therapeutics to market. The event takes place from November 3rd – 5th in Amsterdam.
The conference agenda features scientific tracks covering in-depth discovery, development and manufacturing strategies, trends and technologies across the entire oligonucleotide and peptide spectrum. Inverna Therapeutics looks forward to learning from world-renowned speakers, case studies, and new data whilst participating in sessions, and engaging with potential new collaboration partners.
“TIDES is a good opportunity for Inverna to be updated on discovery strategies, clinical progress, and CMC approaches from industry-leading companies – and to share and discuss our own experiences with precision RNA therapeutics.”
said Poul Sørensen, CEO of Inverna Therapeutics.
About Inverna Therapeutics
Inverna Therapeutics is a Danish biotech company, founded in 2024 emerging from Southern Danish University in Odense, nurtured by Argobio Studio, a launch platform for Europe’s best medicinal science. With our proprietary drug discovery platform, we’re dedicated to developing transformative RNA therapeutics based on precision RNA splicing modulation. Our unique technology allows us to design, test, and develop highly specific activators of pseudo-exons in disease-relevant target RNA. Today, we are pursuing breakthroughs in neurological disorders such as Parkinson’s disease, somatic repeat expansion diseases, and Huntington’s disease, knowing that the approach can extend to other organ systems and diseases.
Contact :
- Poul Sørensen, CEO of Inverna Therapeutics
- psorensen@invernatx.com
